TBPH — Theravance Biopharma Balance Sheet

0.000.00%

Last trade - 00:00

HealthcareBalancedMid CapNeutral

Annual balance sheet for Theravance Biopharma, fiscal year end - December 31st, USD millions except per share, conversion factor applied.

	2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st
Period Length:	—	—	—	—	—
Source:	10-K	10-K	10-K	10-K	10-K
Standards:	USG	USG	USG	USG	USG
Status:	Final	Final	Final	Final	Final
Cash and Equivalents
Short Term Investments
Cash and Short Term Investments	293	173	327	102	88.3
Net Total Accounts Receivable
Net Total Receivables	69.7	57.6	16.8	17.5	68.4
Prepaid Expenses
Total Current Assets	393	250	353	134	161
Gross Property, Plant And Equipment
Accumulated Depreciation
Net Property, Plant And Equipment	59.7	53.3	52	45.4	35.8
Long Term Investments
Long Term Notes Receivable
Other Long Term Assets
Total Assets	469	375	607	382	354
Accounts Payable
Accrued Expenses
Notes Payable / Short Term Debt
Current Portion of Long Term Debt / Capital Leases
Total Other Current Liabilities
Total Current Liabilities	124	58.6	28.7	24.8	32.1
Long Term Debt
Total Long Term Debt
Total Debt
Total Other Liabilities
Total Liabilities	773	713	166	169	179
Non Redeemable Preferred Stock
Common Stock
Additional Paid In Capital
Retained Earnings (Accumulated Deficit)
Other Equity
Total Equity	-304	-339	442	213	176
Total Liabilities & Shareholders' Equity	469	375	607	382	354
Total Common Shares Outstanding